ScholarGate
Assistent

Compara mètodes

Revisa els mètodes seleccionats l'un al costat de l'altre; les files que difereixen es ressalten.

Assaig Clínic de Fase I Multicèntric×Anàlisi dosi-resposta×
CampEpidemiologiaEpidemiologia
FamíliaProcess / pipelineProcess / pipeline
Any d'origen1970s–1980s (formalized in FDA Phase I guidance 1977; ICH E6 GCP 1996)Conceptual roots 16th century; modern epidemiological application mid-20th century
Autor originalEstablished through FDA regulatory guidance and ICH harmonization frameworksParacelsus (conceptual foundation); formalized by John Snow and later Bradford Hill
TipusInterventional clinical study designQuantitative analytical method
Font seminalInternational Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). (2016). ICH Harmonised Guideline: Integrated Addendum to ICH E6(R1): Guideline for Good Clinical Practice E6(R2). ICH. link ↗Rothman, K. J., Greenland, S., & Lash, T. L. (2008). Modern Epidemiology (3rd ed.). Lippincott Williams & Wilkins. ISBN: 978-0781755641
Àliesmultisite Phase I trial, multi-institutional Phase I study, Phase I dose-escalation multicenter study, first-in-human multicenter trialexposure-response analysis, concentration-response modeling, dose-response modeling, DRA
Relacionats64
ResumA multicenter Phase I clinical trial is the first systematic administration of an investigational agent to humans, conducted simultaneously across two or more clinical sites. Its primary objectives are to characterize the safety and tolerability profile of the intervention, determine the maximum tolerated dose (MTD), and describe pharmacokinetic and pharmacodynamic behavior. Distributing enrollment across sites increases participant accrual speed and enhances the generalizability of early-phase safety data.Dose-response analysis quantifies the relationship between the magnitude of an exposure (the dose) and the probability or rate of an outcome (the response). It is a core analytical strategy in epidemiology and toxicology, providing evidence that increasing exposure systematically increases — or decreases — the risk of disease. A demonstrated dose-response gradient is one of Bradford Hill's classic criteria supporting causal inference.
ScholarGateConjunt de dades
  1. v1
  2. 2 Fonts
  3. PUBLISHED
  1. v1
  2. 2 Fonts
  3. PUBLISHED

Ves a la cerca Baixa les diapositives

ScholarGateCompara mètodes: Multicenter Phase I Clinical Trial · Dose-Response Analysis. Recuperat el 2026-06-18 de https://scholargate.app/ca/compare